Navigation Links
Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
Date:3/7/2013

Norwood, MA (PRWEB) March 07, 2013

As we get closer to the American College of Cardiology (ACC) meeting 9-11 March, BioPharm Insight has put together a snapshot of forward-looking cardiovascular (CV) disease coverage. To view the full report, start a free trial today.

CV-related diseases are the number one cause of death globally, with an estimated incidence rate of 17.3 million people, according to World Health Organization (WHO) 2008 statistics. Besides antiplatelets and antithrombotic therapies, oral anticoagulants have been prescribed to prevent CV disease, replacing the cumbersome standard-of-care, warfarin.

In January 2013, BioPharm Insight reported that Daiichi Sankyo's Phase III Lixiana (edoxaban) stroke prevention drug is not viewed as differentiated enough from already-approved drugs such as Boehringer Ingelheim's Pradaxa (dabigatran), Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Bristol-Myers Squibb/Pfizer's Eliquis (apixaban).

WHO's data shows 7.5 million deaths, or 13% of all CV-related deaths, can be attributed to raised blood pressure. Of those 7.5 million deaths, 51% are due to stroke and 45% are due to coronary heart disease. Cholesterol accumulation in blood vessels is a major risk factor for stroke and heart disease.

On 14 December 2012, BioPharm Insight reported that Merck's Vytorin (simvastin/ezetimibe) and Zetia (ezetimibe) cholesterol drug sales could be negatively impacted should the IMPROVE-IT CV outcomes trial for Vytorin fail to demonstrate a significant reduction in events. Experts also believe that due to the recent failure of the HPS2-THRIVE outcomes trial of Merck's "good" cholesterol-raising (HDL) drug Tredaptive, the FDA is apt to require CV outcomes results for Merck’s other combination drug, Zetia/atorvastatin prior to approval.

While enthusiasm for the cholesteryl ester transfer protein (CETP) inhibitor class dwindles after the HPS2-THRIVE trial failed to meet its endpoint, anti-PCSK9 strategies such as those by Regeneron Pharmaceuticals, Sanofi and Amgen have garnered a great deal of enthusiasm. This past November, BioPharm Insight reported that Regeneron/Sanofi's SAR236553/REGN727 and Amgen's AMG 145 were likely to yield similarly efficacious cholesterol-lowering effects in Phase III assessment.

Additional report highlights include:

  •     AMG 145, an anti-PCK9, proves an unlikely fit for homozygous familial hypercholesterolemia (hoFH).
  •     Aegerion faces uncertainty in its quest for EU approval of Juxtapid.
  •     GlaxoSmithKline's atherosclerosis candidate darapladib faces low prospects of demonstrating significant CV event reduction.

Access all of BioPharm Insight’s reports by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10499702.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
2. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. PDL BioPharma Completes Regular Quarterly Dividend Payment
8. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
11. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/5/2016)... FRANCISCO , February 5, 2016 ... a biotechnology company focused on developing products for ... has requested Rare Pediatric Disease Designation (RPDD) from the ... pigmentosa (RP) with MANF. MANF was previously granted orphan ... 2014. --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced today that Edward Lanphier , Sangamo,s president ... the progress of Sangamo,s ZFP Therapeutic ® development ... at 2:40 pm ET on Thursday, February 11, 2016, ... Healthcare Conference. The conference is being held in ...
Breaking Biology Technology:
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... Jan. 25, 2016  Glencoe Software, the world-leading supplier ... publication industries, will provide the data management solution OMERO ... Photo ... Phenotypic analysis measures the characteristics ... allowing comparisons between states such as health and disease, ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
Breaking Biology News(10 mins):